Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICE Study: Irinotecan, Cetuximab, and Envafolimab Rechallenge in mCRC
NCT06321081Phase 2Recruiting
- Sponsor
- Beijing Hospital
- Start
- Mar 2024
- Primary completion
- Dec 2026
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of envafolimab in colorectal cancer (CRC), sponsored by Beijing Hospital. Started Mar 2024; status: recruiting.
02
Drugs
envafolimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06321081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06321081.